BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong SN, Kim HJ, Kim KH, Han SJ, Ahn IM, Ahn HS. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2017;45:253-263. [PMID: 27933686 DOI: 10.1111/apt.13851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Yamamoto-Furusho JK, Sarmiento-Aguilar A, Parra-Holguín NN, Bozada-Gutiérrez KE. Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. Rev Gastroenterol Mex (Engl Ed) 2019;84:11-7. [PMID: 29605092 DOI: 10.1016/j.rgmx.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lee J, Im JP, Han K, Park S, Soh H, Choi K, Kim J, Chun J, Kim JS. Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease: A nationwide, population-based study. World J Gastroenterol 2019; 25(42): 6354-6364 [PMID: 31754295 DOI: 10.3748/wjg.v25.i42.6354] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Goren I, Brom A, Yanai H, Dagan A, Segal G, Israel A. Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study. United European Gastroenterol J 2020;8:195-203. [PMID: 32213075 DOI: 10.1177/2050640619874524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Wang X, Wong SH, Wang XS, Tang W, Liu CQ, Niamul G, Wu B, Tam LS, Wu JCY, Chan FKL, Sung JJY, Ng SC. Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. Rheumatology (Oxford) 2019;58:803-10. [PMID: 30561745 DOI: 10.1093/rheumatology/key364] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Forgie AJ, Fouhse JM, Willing BP. Diet-Microbe-Host Interactions That Affect Gut Mucosal Integrity and Infection Resistance. Front Immunol 2019;10:1802. [PMID: 31447837 DOI: 10.3389/fimmu.2019.01802] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
6 Banerjee R, Pal P, Nabi Z, Shava U, Ganesh G, Reddy DN. Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease. Intest Res 2021;19:398-407. [PMID: 33207854 DOI: 10.5217/ir.2020.00107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kim HJ, Kang TU, Swan H, Kang MJ, Kim N, Ahn HS, Park SM. Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones. Dig Dis Sci. 2018;63:3465-3473. [PMID: 30171402 DOI: 10.1007/s10620-018-5262-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Song JH, Hong SN, Lee JE, Kim K, Kim TJ, Kim ER, Chang DK, Kim YH. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease. Scand J Gastroenterol 2019;54:876-85. [PMID: 31303093 DOI: 10.1080/00365521.2019.1638962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in Crohn's disease in patients from Asian countries in the GEMINI 2 study. Intest Res 2021;19:83-94. [PMID: 33378612 DOI: 10.5217/ir.2019.09160] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Weng MT, Tung CC, Chang YT, Leong YL, Wang YT, Wong JM, Wei SC. Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015. J Clin Med 2018;7:E394. [PMID: 30373275 DOI: 10.3390/jcm7110394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
11 Park S, Chun J, Han KD, Soh H, Choi K, Kim JH, Lee J, Lee C, Im JP, Kim JS. Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study. World J Gastroenterol 2018; 24(42): 4798-4808 [PMID: 30479466 DOI: 10.3748/wjg.v24.i42.4798] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
12 Lee JY, Oh K, Hong HS, Kim K, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Lee HS, Jo KW, Park SH. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea. BMC Gastroenterol 2021;21:390. [PMID: 34670529 DOI: 10.1186/s12876-021-01973-5] [Reference Citation Analysis]
13 Lau CS, Chen YH, Lim K, de Longueville M, Arendt C, Winthrop K. Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data. Clin Rheumatol 2021;40:867-75. [PMID: 32740672 DOI: 10.1007/s10067-020-05248-4] [Reference Citation Analysis]
14 Banerjee R, Ali RAR, Wei SC, Adsul S. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut Liver 2020;14:685-98. [PMID: 33191310 DOI: 10.5009/gnl19209] [Reference Citation Analysis]
15 Kim J, Im JP, Yim JJ, Lee CK, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, Cheon JH. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy. Korean J Gastroenterol 2020;75:29-38. [PMID: 31986571 DOI: 10.4166/kjg.2020.75.1.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Choi YJ, Lee DH, Shin DW, Han K, Yoon H, Shin CM, Park YS, Kim N. Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study. Aliment Pharmacol Ther 2019;50:769-79. [DOI: 10.1111/apt.15446] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]